Loading...
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success
PURPOSE: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and...
Saved in:
| Published in: | Breast Cancer Res Treat |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer US
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6586706/ https://ncbi.nlm.nih.gov/pubmed/31065872 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-019-05261-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|